Purevax RCP FeLV Europäische Union - Deutsch - EMA (European Medicines Agency)

purevax rcp felv

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Purevax RCP FeLV ad us. vet. Lyophilisat und Suspension zur Herstellung einer Injektionssuspension für Katzen Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

purevax rcp felv ad us. vet. lyophilisat und suspension zur herstellung einer injektionssuspension für katzen

boehringer ingelheim (schweiz) gmbh - feline rhinotracheitis virus (herpesvirus fhv), strain f2, live attenuated, feline calicivirus antigens (fcv), strains 431 and g1, inactivated, feline panleukopenia virus (fpv), strain pli iv, live attenuated, feline leukemia virus (felv) recombinant of canarypox virus, strain vcp97, live - lyophilisat und suspension zur herstellung einer injektionssuspension für katzen - praeparatio cryodesiccata: feline rhinotracheitis virus (herpesvirus fhv), strain f2, live attenuated ≥ 10^4.9 u., feline calicivirus antigens (fcv), strains 431 and g1, inactivated ≥ 2.0 u., feline panleukopenia virus (fpv), strain pli iv, live attenuated ≥ 10^3.5 u., saccharum, sorbitolum, dextranum 40, caseinum hydrolysatum, collagenum hydrolysatum, dikalii phosphas anhydricus, kalii dihydrogenophosphas, kalii hydroxidum, pro dosi. i) suspension 0.5 ml: feline leukemia virus (felv) recombinant of canarypox virus, strain vcp97, live ≥ 10^7.2 u., kalii chloridum, natrii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesii chloridum hexahydricum, calcii chloridum dihydricum, aqua ad iniectabile, ad suspensionem pro dosi 0.5 ml. ii) suspension 1 ml: feline leukemia virus (felv) recombinant of canarypox virus, strain vcp97, live ≥ 10^7.2 u., kalii chloridum, natrii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, magnesii chloridum hexahydricum, calcii chloridum dihydricum, aqua ad iniectabile, ad suspensionem pro dosi 1 ml. - attenuierter lebendimpfstoff gegen felines rhinotracheitis- und panleukopenievirus und inaktivierter impfstoff gegen felines calicivirus und lebendimpfstoff des kanarienpockenvirus gegen felines leukämievirus bei katzen - impfstoffe